Drugs in R & D

, Volume 2, Issue 4, pp 249–250 | Cite as

MK 869

L 754030, MK 0869
Section 1: Antiemetics in Oncology Adis R&D Profile


Adis International Limited Paroxetine Sexual Dysfunction Granisetron Single Oral 400mg Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Elwood W. Dawn of a new era with substance P antagonists in depression? Inpharma 1998 Sep 12; 1154: 9–10Google Scholar
  2. 2.
    Feighner JP. Substance P. Eur Neuropsychopharmacol 1998 Nov; 8 Suppl. 2: 85CrossRefGoogle Scholar
  3. 3.
    Tattersall FD, Rycroft W, Hale JJ, et al. The NK1 receptor antagonist L-754,030 and its N-phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in the ferret. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles, 253Google Scholar
  4. 4.
    Navari RM, Reinhardt RR, Gralla RJ, L-754,030 Antiemetic Trials Group, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999 21 Jan; 340: 190–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations